Sirtex Medical US Holdings, Inc., a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS™, an innovative system for the delivery of SIR-Spheres® Y-90 resin microspheres.
SIROS™ provides precise, simple and versatile solution for interventional radiologists to deliver patient-tailored care
SIROS™ offers a visual, intuitive and versatile option for interventional radiologists to deliver SIR-Spheres® to patients with liver cancer. With the system’s visually controlled administration, physicians can determine and adjust the precise quantity and speed of SIR-Spheres® microspheres delivery. Additionally, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.
SIROS™ intuitive design features a peel-and-place tubing set, a proprietary needleless D-Vial specifically designed to suspend SIR-Spheres® into a vortex that may allow for a more even distribution, and a locking cover to safely secure the microspheres during delivery. A three-step setup further provides quick and simple administration and disposal.
“SIROS™ brings world-class expertise and innovation together to provide interventional radiologists with the support and technology they need to treat patients with liver cancer,” said Kevin R. Smith, Chief Executive Officer of Sirtex. “As established leaders in the industry for more than 20 years, we are pleased to add SIROS™ to our expanding portfolio of technology designed to advance patient care.”
Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 45 countries. For more information, visit www.sirtex.com. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.